Search | Clinical Trials Finder

Conditions: Myelodysplastic Syndromes
Interventions: PR1 leukemia peptide vaccine, incomplete Freund's adjuvant, sargramostim; Biological
Lead sponsor: The Vaccine Company; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer, Pancreatic Cancer, Small Intestine Cancer
Interventions: carcinoembryonic antigen peptide 1-6D, incomplete Freund's adjuvant, sargramostim; Biological
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Triple-Negative Breast Cancer (TNBC)
Interventions: BreakVax, Ipilimumab 2.5 mg, Pembrolizumab, Standard-of-care chemotherapy, Losartan and aspirin; Drug
Lead sponsor: BreakBio Corp; Industry
Eligibility: 18 Years to 72 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Interventions: PSA:154-163(155L) peptide vaccine, incomplete Freund's adjuvant, laboratory biomarker analysis; Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Ovarian Cancer Stage IV, Ovarian Cancer Stage III, Ovarian Cancer Stage 3
Interventions: NY-ESO-1 Peptide vaccine, Toripalimab-tpzi; Biological · Drug
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Hackensack, New Jersey

Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma, Iris Melanoma, Stage IIB Melanoma, Stage IIC Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma
Interventions: tyrosinase peptide, gp100 antigen, MART-1 antigen, incomplete Freund's adjuvant, Montanide ISA 51 VG, sargramostim, laboratory biomarker analysis; Biological · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Leukemia
Interventions: PR1 leukemia peptide vaccine, sargramostim, placebo; Biological · Other
Lead sponsor: The Vaccine Company; Industry
Eligibility: 18 Years and older
Enrollment: 244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 15
States / cities: Scottsdale, Arizona • Los Angeles, California • South San Francisco, California + 10 more

Conditions: Renal Cell Carcinoma
Interventions: incomplete Freund's adjuvant, von Hippel-Lindau peptide vaccine; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Colorectal Cancer
Interventions: EO2040; Drug
Lead sponsor: Enterome; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Metastatic Breast Cancer, HER2-positive Breast Cancer, EGFR Overexpression, Metastatic Esophageal Carcinoma, HER-2 Positive Esophageal Cancer
Interventions: Combination of MVF-HER-2 (597-626) and MVF-HER-2 (266-296) emulsified with ISA 51; Biological
Lead sponsor: Pravin T.P Kaumaya; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Indianpolis, Indiana

Conditions: Malignant Pleural Mesothelioma
Interventions: Galinpepimut-S + Montanide + GM-CSF, Montanide + GM-CSF; Biological
Lead sponsor: Sellas Life Sciences Group; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Yellow Fever, Yellow Fever Immunisation
Interventions: ISA-720, MVA Smallpox Vaccine, MVA-BN Yellow Fever Vaccine, Placebo, YF Vax 17D Strain; Drug · Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 2
States / cities: Iowa City, Iowa • St Louis, Missouri

Conditions: Melanoma, Squamous Cell Carcinoma of Head and Neck
Interventions: IO102-IO103, Pembrolizumab KEYTRUDA®; Drug
Lead sponsor: IO Biotech; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 3
States / cities: New Haven, Connecticut • Boston, Massachusetts • Richmond, Virginia

Conditions: Melanoma
Interventions: Glycoprotein 100 (GP100): 209-217 (210M), Interleukin-2 (IL-2), Montanide ISA 51, Melanoma antigen recognized by T-cells (MART)-1: 27-35, 27-35 (27L): melanoma antigen recognized by T-cells (MART)-1, melanoma antigen recognized by T-cells (MART)-1: 26-35(27L); Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 7 Years and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Acute Myeloid Leukemia
Interventions: Galinpepimut-S, Azacitidine, Venetoclax, Decitabine, Cytarabine, Observation, GM-CSF, Montanide; Biological · Drug · Other
Lead sponsor: Sellas Life Sciences Group; Industry
Eligibility: 18 Years and older
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 17
States / cities: Birmingham, Alabama • Los Angeles, California • Whittier, California + 14 more

Conditions: Breast Cancer
Interventions: OCPM Immunotherapeutic Vaccine; Biological
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Multiple Myeloma
Interventions: Galinpepimut-S, GM-CSF, Montanide, lenalidomide, bortezomib; Biological · Other · Drug
Lead sponsor: Sellas Life Sciences Group; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Epithelial Ovarian, Tubal or Peritoneal Cancer
Interventions: tumor peptide vaccine; Biological
Lead sponsor: Michael Morse, MD; Other
Eligibility: 18 Years and older · Female only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Melanoma
Interventions: MDX-CTLA4 Antibody; Tyrosinase/gp100/MART-1 Peptides Melanoma Vaccine; Biological
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Glioblastoma, Glioma
Interventions: Bevacizumab, Peptide Vaccine, Poly-ICLC as immune adjuvant, Keyhole limpet hemocyanin (KLH); Drug · Biological
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Melanoma (Skin)
Interventions: gp100 antigen, incomplete Freund's adjuvant, sargramostim, tyrosinase peptide; Biological
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2002
U.S. locations: 2
States / cities: Los Angeles, California • Ann Arbor, Michigan

Conditions: Cancer
Interventions: Intracel KLH Vaccine, Biosyn KLH, Montanide ISA51, Tetanus toxoid; Biological · Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2012
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer
Interventions: decitabine, NY-ESO-1 peptide vaccine, pegylated liposomal doxorubicin hydrochloride, sargramostim, incomplete Freund's adjuvant, immunohistochemistry staining method, liquid chromatography, mass spectrometry, reverse transcriptase-polymerase chain reaction, laboratory biomarker analysis, DNA methylation analysis, enzyme-linked immunosorbent assay; Drug · Biological · Other + 1 more
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Mosquito-Borne Infectious Diseases
Interventions: AGS-v PLUS Vaccine, Montanide ISA-51 Adjuvant, Alhydrogel® Adjuvant, Saline Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Vaccine Therapy and GM-CSF in Treating Patients With Low-Risk or Intermediate-Risk Myelodysplastic Syndrome

Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract

Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple Negative Breast Cancer Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy

Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer

A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients

Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma

Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia in Remission

Vaccine Therapy With Tumor Specific Mutated VHL Peptides in Adult Cancer Patients With Renal Cell Carcinoma

EO2040 in Combination With Nivolumab, for Treatment of Patients With Minimal Residual Disease of Colorectal Cancer

HER-2 B Cell Peptide Vaccine

Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy

A Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy Volunteers

Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors

Peptide Vaccination for Patients at High Risk for Recurrent Melanoma

Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2

Study of Cancer Peptides Vaccine Plus GM-CSF as Adjuvant Treatment for High Risk (TXN2-3M0) or Metastatic Breast Cancer With No Evidence of Disease

WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation

A Phase I Study of Ovarian Cancer Peptides Plus GM-CSF and Adjuvant With Ovarian, Tubal or Peritoneal Cancer

Novel Adjuvants for Peptide-Based Melanoma Vaccines

A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma

Vaccine Therapy in Treating Patients With Stage II Melanoma That Can Be Removed by Surgery

Vaccination With Tetanus and KLH to Assess Immune Responses.

Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Evaluating the Safety and Immunogenicity of AGS-v PLUS, a Universal Mosquito-Borne Disease and Mosquito Control Vaccine